The following abstracts represent the presentations given at IWWM-9 (Amsterdam-2016), Session 12: Great Debate I - What should be the frontline standard for treatment of WM?:

Session Moderator: Christian Buske (Germany)

Overview: Do frontline treatments for WM reflect regional economics and practice patterns? C. Buske (Germany)

Should Bendamustine be the standard for frontline treatment of WM? C. Buske (Germany)

Should Cyclophosphamide based therapy (CDR) be the standard for frontline treatment of WM? E. Terpos (Greece)

Should Nucleoside analogues be the standard for frontline treatment of WM? V. Leblond (France)

Should proteasome inhibitors be the standard for frontline treatment of WM? JJ Castillo (USA)

Should ibrutinib be the standard for frontline treatment of WM? M. Dimopoulos (Greece)